Blue Shield returns profits

Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

The effects of breast cancer can remain long after the disease has left the body, serving as a traumatic daily reminder.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

A single-center retrospective study found the approval and use of new agents to treat chronic graft-versus-host disease (GVHD) is associated with quality-of-life improvements.

Here’s what you missed this week on Managed Healthcare Executive.